Diasome Pharmaceuticals is a clinical-stage diabetes therapeutics company that designs and develops insulin-based therapies.
Diasome Pharmaceuticals has raised $9.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2023.
Diasome Pharmaceuticals's investors include Medicxi, JDRF T1D Fund, Quaker BioVentures, Devon Park BioVentures, McDonald Partners.
Diasome Pharmaceuticals is headquartered in Cleveland, United States.
Diasome Pharmaceuticals is a clinical-stage diabetes therapeutics company that designs and develops insulin-based therapies.
Diasome Pharmaceuticals is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Diasome Pharmaceuticals — Funding & Investors." VCBacked, June 30, 2023, https://www.vcbacked.co/company/diasome-pharmaceuticals. Accessed September 30, 2026.
VCBacked. (2023). Diasome Pharmaceuticals — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/diasome-pharmaceuticals
{{cite web |title=Diasome Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/diasome-pharmaceuticals |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated